Recent advances and future directions in targeting MYCN: From undruggable to druggable.
Abstract
MYCN is a member of the MYC family of transcription factors and a potent oncogenic driver across neural crest, neuroectodermal, and neuroendocrine malignancies, including neuroblastoma, where MYCN amplification remains one of the most powerful molecular predictors of treatment failure and poor survival. MYCN has long been considered an ideal therapeutic target, given its restricted expression in postnatal tissues and potent oncogenic activity. However, direct and selective MYCN targeting therapies have yet to be established and translated into the clinic. This reflects the challenges of drugging MYC family proteins, which lack enzymatic active sites and defined binding pockets targeted by conventional small molecules. Here, we examine the landscape of MYCN targeting strategies, from direct approaches such as MYC-MAX dimerization inhibitors to indirect approaches targeting MYCN expression, its interactors, and downstream oncogenic dependencies. We also highlight the potential of targeted protein degrader technology for directly and selectively depleting MYCN protein. We further discuss the profound immunosuppressive tumor microenvironment characteristic of MYCN-amplified neuroblastoma and the therapeutic vulnerabilities this creates. Together, these advances in understanding and technology present a renewed opportunity to translate four decades of MYCN biology into effective therapies to improve outcomes for patients with neuroblastoma and other MYCN-driven cancers.